Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenue

Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer, manufacturing and supply of sterile injectable products. The agreement covers 55 SKUs across three sites, with annualised revenue potential of $90-100 million upon commercialisation. Revenue generation is expected to begin in 2029.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aBfGJPW
via IFTTT